our approach

Bridging the gap

Over the last decade, venture capital funding shifted away from early-stage companies in favour of later-stage opportunities in an effort to minimize risk, creating a financing gap in the commercialization pathway.

Accel-Rx was created to bridge that gap and is the only organization with a national perspective addressing these specific growth challenges.

Stage of development and funding source
Accel-rx stages of funding graph Accel-rx stages of funding graph Accel-rx stages of funding graph

Accel-Rx, and founding partner, BDC Capital, provide up to $1M in funding which is further matched by third-party investors. Supporting capital financing needs is just one part of the solution – Accel-Rx also offers a full range of programs to address early-stage operating needs including mentorship, business services, training, and networking.

Building on promise

Accel-Rx draws from networks across the country to find the most promising opportunities. Once identified, Accel-Rx employs its own proprietary filter with the aid of their Investment Committee – a group of highly qualified and diverse panel of experts – and a network of external consultants, to determine those with the highest potential.

Initial Filter

Industry investment filter

Accel-Rx Filter

Accel-rx investment filter

Thousands of technologies discovered across the country are filtered down first through translational centers and then through Accel-Rx’s proprietary filter to determine companies with the highest potential to scale and succeed as the next generation of anchor companies.

investment philosophy


Accel-Rx invests in promising start-ups by providing an infusion of capital and talent in order to support the growth into venture-ready companies (able to raise a series A or similar financing) within 12 to 24 months. Investment decisions are made based on internal and external diligence as well as a recommendation by the Accel-Rx Investment Committee, which is comprised of industry experts from a range of therapeutic and specialty areas.

 

Investment by Accel-Rx is a competitive process and therefore funding decisions rely heavily on our comprehensive screening process.

 

Providing they meet eligibility requirements, opportunities are evaluated based on the following investment criteria:

 

  • Pharmaceutical, medical device or diagnostic product
  • Quality and competitive advantage of technology
  • High growth and unmet market opportunity
  • Quality of the management
  • Validated development plan
  • Impact of seed money: getting to a value inflection point
  • Type of co-investors (required third-party match)
  • Scope and strength of IP protection
  • Participation in Accel-Rx programs
  • Return on investment for Accel-Rx and its stakeholders
investment philosophy

Impact

16

Investment
forums

Number of investment meetings participated in

$20.1M

Co-invested

Amount of money co-invested by external investors

12

Partnerships

Number of organizations Accel-Rx has worked with to fulfill its mandate

13

Term
Sheets

Number of term sheets that have been signed

19

Full
proposals

Number of companies that have submitted full proposals

48

Pre-proposals

Number of companies that have submitted pre-proposals

148

Initial
Reviews

Number of companies Accel-Rx has screened

06

Investments

Number of completed investments

7.6

Financial
Leverage
ratio

The ratio of external funding to Accel-Rx investment

16

Investors
engaged

Number of co-investors in Accel-Rx investments excluding Angels

$3.0M

Invested

Amount of seed capital invested by Accel-Rx

meet our leadership team

who we are